Novo Nordisk: Canada approves expanded use of Victoza.
(CercleFinance.com) - Denmark's Novo Nordisk said on Tuesday that Health Canada has approved Victoza to reduce the risk of cardiovascular death in patients with type-2 diabetes and cardiovascular diseases.
Victoza is now approved to reduce the incidence of cardiovascular death in patients with type-2 diabetes and established cardiovascular diseases when added to diet, exercise, and the current standard of care therapy.
Novo Nordisk said the product update for Victoza has been supported by results from a long-term trial that showed that Victoza reduced the risk of cardiovascular death, heart attack and non-fatal stroke by 13% versus placebo.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Victoza is now approved to reduce the incidence of cardiovascular death in patients with type-2 diabetes and established cardiovascular diseases when added to diet, exercise, and the current standard of care therapy.
Novo Nordisk said the product update for Victoza has been supported by results from a long-term trial that showed that Victoza reduced the risk of cardiovascular death, heart attack and non-fatal stroke by 13% versus placebo.
Copyright (c) 2017 CercleFinance.com. All rights reserved.